STENYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends March 31
STERIS plc
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$221.97−0.69 (-0.31%)
Close on Oct 19, 2026
- Market cap
- $21.73B
- P/E (TTM)
- 27.1
- Dividend yield
- 1.11%
Margins
Share of revenue, fiscal years 2016 to 2026
Gross margin
44.2%+1.0 pts over 5 years
Operating margin
18.6%+0.9 pts over 5 years
Net margin
13.2%+0.4 pts over 5 years
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +8.7% | +9.4% | +13.8% | – | |
| Gross profit | +9.3% | +9.9% | +14.4% | – | |
| Operating income | +27.1% | +11.7% | +15.0% | – | |
| Net income | +27.3% | +94.1% | +14.5% | – | |
| EPS, diluted | +27.9% | +95.0% | +11.4% | – | |
| Free cash flow | +25.0% | +35.0% | +16.6% | – | |
| Dividend per share | +10.3% | +10.2% | +9.4% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2021 | FY2026 | Trend |
|---|---|---|---|---|
| Return on equity | – | 10.9% | 11.3% | |
| Return on assets | – | 6.6% | 7.5% | |
| Current ratio | – | 2.10 | 2.09 | |
| Debt to equity | – | 0.43 | 0.27 | |
| Net debt to EBITDA | – | 1.86× | 0.94× | |
| Interest coverage | 5.1× | 14.7× | 18.2× | |
| Inventory turnover | – | 6.1× | 5.5× | |
| Capex to revenue | 6.6% | 7.7% | 6.2% | |
| Diluted shares | 86M | 86M | 99M |
Where the cash went
Fiscal 2022 to 2026, five years combined
Steris generated $4.90B from operations and spent $3.58B on capital expenditure, dividends and share buybacks. 49% of that went back into the business.
Generated
$4.90B
Used
$3.58B
Capital expenditure$1.75B49%Dividends$1.01B28%Share buybacks$822.94M23%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin13.2%
×Asset turnover0.57×
×Equity multiplier1.51×
=Return on equity, FY202611.3%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2026 | 13.2% | 0.57× | 1.51× | 11.3% |
| FY2025 | 11.3% | 0.51× | 1.64× | 9.5% |
| FY2024 | 7.4% | 0.47× | 1.77× | 6.1% |
| FY2023 | 2.4% | 0.41× | 1.76× | 1.7% |
| FY2022 | 5.8% | 0.47× | 1.73× | 4.7% |
| FY2021 | 12.8% | 0.52× | 1.65× | 10.9% |
| FY2020 | 13.5% | 0.58× | 1.60× | 12.4% |
| FY2019 | 10.9% | 0.54× | 1.61× | 9.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
9of 9 tests passed in fiscal 2026. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$782.30M
- Cash generatingOperating cash flow above zero$1.34B
- Return on assets improvedROA up on the prior year5.6% → 7.7%
- Earnings backed by cashOperating cash flow above net income$1.34B vs $782.30M
- Less leverageLong-term debt to assets fell18.9% → 16.9%
- Better liquidityCurrent ratio rose1.96 → 2.09
- No dilutionShare count did not rise99M → 99M
- Gross margin improvedGross margin up on the prior year44.01% → 44.25%
- More efficientAsset turnover rose0.49 → 0.59